Vertex Pharmaceuticals Inc

News & Events zu Vertex Pharmaceuticals Inc (VRTX)

$541.690

-5.796 (-1.07%)Zum Schluss

VRTX-News

VRTX-Events

8/10 10:00

Vertex Stock Rises $30.33 to $526.40

Notable gainers among liquid option names this morning include Vertex (VRTX) $526.40 +30.33, Akamai (AKAM) $117.12 +6.58, Apache (APA) $39.61 +1.98, NetApp (NTAP) $199.43 +9.91, and Super Micro (SMCI) $32.71 +1.58.

7/29 07:30

AbCellera Collaborates with Vertex to Develop Multispecific T-Cell Engagers

AbCellera (ABCL) announced a collaboration with Vertex Pharmaceuticals Incorporated (VRTX) to research, develop, manufacture, and commercialize multispecific T-cell engagers, TCEs, for autoimmune diseases and other conditions. Under the terms of the agreement, AbCellera will leverage its proprietary TCE platform to lead discovery and early development activities. Vertex will fund all research and development costs and will have the right to develop and commercialize therapeutic multispecific antibodies resulting from the collaboration. AbCellera will receive $28M in total upfront payments and is eligible to receive preclinical, development, regulatory, and commercial milestone payments, along with tiered royalties on net sales. In addition, AbCellera and Vertex may mutually agree to have AbCellera perform cell line development, process development, and clinical manufacturing through Phase 1 for any program under the collaboration.

7/7 16:30

TD Cowen Downgrades Crinetics to Hold

TD Cowen analyst Tyler Van Buren downgraded Crinetics (CRNX) to Hold from Buy with no price target after Vertex Pharmaceuticals (VRTX) announced an agreement to acquire the the company for $85 per share in cash. Given the "impressive" 102% premium, the firm expects the deal to close Q3 and adds that Vertex "will receive one of the most robust endocrine pipelines."

Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.

Kostenlos starten